www.actemrahcp.com Review:
ACTEMRA® RA Treatment Information for Rheumatologists - Find valuable ACTEMRA® (tocilizumab) information, including an ACTEMRA® dosing calculator, RA patient brochure, ACTEMRA® prescription guide and the ISI. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/about.html About ACTEMRA® Efficacy & ACTEMRA® Clinical Trials - Discover information about the proposed MOA of ACTEMRA® (tocilizumab), how it targets and inhibits IL-6 signaling, and ACTEMRA® clinical trials. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/contact-genentech-representative.html Contact an ACTEMRA® (tocilizumab) HCP Representative - Contact an ACTEMRA® representative to answer any additional questions you or your colleagues may have about SJIA, PJIA or RA treatment with ACTEMRA®. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/references.html ACTEMRA® (tocilizumab) RA, SJIA & PJIA References - Find healthcare professional references including clinical trials and medical journals written about ACTEMRA® efficacy in PJIA, SJIA and RA treatment. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/pjia.html ACTEMRA® PJIA Treatment Information for Rheumatologists - Find valuable ACTEMRA® (tocilizumab) information, including an ACTEMRA® dosing calculator, PJIA patient brochure, ACTEMRA® prescription guide and the ISI. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/sjia.html ACTEMRA® SJIA Treatment Information for Rheumatologists - Find valuable ACTEMRA® (tocilizumab) information, including an ACTEMRA® dosing calculator, SJIA patient brochure, ACTEMRA® prescription guide and the ISI. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/ra/dosing-and-monitoring.html ACTEMRA® Dosing Calculator for RA Treatment - Find the ACTEMRA® (tocilizumab) dosing calculator that can quickly assess and help prescribe ACTEMRA® dosing for rheumatoid arthritis treatment. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/ra/dosing-and-monitoring/patient-monitoring.html ACTEMRA® Patient Monitoring & RA Management - Find information about ACTEMRA® (tocilizumab) patient monitoring and management, and any possible ACTEMRA® side effects or laboratory abnormalities. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/ra/clinical-study-safety.html ACTEMRA® RA Clinical Trial Safety Profile Side Effects - Find information regarding the ACTEMRA® (tocilizumab) RA clinical trial safety profile and the possible ACTEMRA® side effects when treating RA. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/ra/patient-financial-support.html ACTEMRA® (tocilizumab) CoPay Card for RA Treatment - Find out if your patient is eligible for the ACTEMRA® CoPay Card, designed to help with the ACTEMRA® cost during RA treatment. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/ra/education-training.html ACTEMRA® (tocilizumab) RA Patient Education Materials - Find valuable ACTEMRA® RA patient education information, including RA patient brochure, ACTEMRA® prescription guide, ISI, and an ACTEMRA® dosing guide. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/sjia/dosing-and-monitoring/dosing-calculator.html#dosing-calc-sjia ACTEMRA® Dosing Calculator for SJIA Treatment - Find the ACTEMRA® dosing calculator that can determine ACTEMRA® (tocilizumab) dosage for systemic juvenile idiopathic arthritis treatment. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/pjia/dosing-and-monitoring/dosing-calculator.html#dosing-calc-pjia ACTEMRA® Dosing Calculator for PJIA Treatment - Find the ACTEMRA® dosing calculator that can help determine ACTEMRA® (tocilizumab) dosing for polyarticular juvenile idiopathic arthritis treatment. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
https://www.actemrahcp.com/site-map.html ACTEMRA® (tocilizumab) Site Map - Find the ACTEMRA (tocilizumab) healthcare professional website site map and find various resources to help patients during SJIA, PJIA and RA treatment. Learn about ACTEMRA® (tocilizumab), an FDA-approved treatment for rheumatoid arthritis, approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). INDICATIONS: ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and death, have occurred. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently. Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Other potential risks of ACTEMRA include demyelinating disorders and malignancies. Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Common adverse reactions in RA studies included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only). Common adverse reactions in SJIA studies included upper respiratory tract infections, headache, nasopharyngitis, and diarrhea. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients. Please see full Prescribing Information including Boxed Warning for additional important safety information.
Country: 52.52.26.231, North America, US
City: -121.8914 California, United States
Suki Michelle - Do Not Cave Into PressureI purchased Xzilon when leasing a car at Kunes Country Ford. It was a hard-sell for Xzilon including a video presentation that suckered me in. DO NOT PURCHASE THIS SERVICE. NOTHING of any relevance or likelihood is covered. It's a total scam and I'm extremely pissed off. Shame on YOU Kunes Country Ford! You lost what could have been a long-term customer.
Areta - Premium for sure!We have used two other carseats in this decade - the chicco keyfit 30 and an evenflo titan. The Maxi-Cosi Pria 70 is .. ugh. It's wonderful. It looks great. It feels extra premium. The fabric is good, shiny, resists pet hair and crumbs. It feels nice. Everything is cushioned. The strap covers don't get all disgusting with a little drool. This car seat is SO PREMIUM.
